ISRCTN45238573已完成未知
HE4/ROMA (Risk of Ovarian Malignancy Algorithm) Evaluation Study in Malaysian Women
Abbott Laboratories (Singapore)0 个研究点目标入组 600 人开始时间: 2014年4月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Female
入选标准
- •1. Malaysian females consenting to undergo surgery based on the finding of adnexal mass.
- •2. Adnexal mass must be verified by imaging.
- •3. Presence of at least one of the ACOG/SCO guideline criteria.
- •4. Able to understand and sign the Informed Consent forms. For females <18 years old, consent will be obtained from their parents or guardian.
排除标准
- •1. Previous history of ovarian or primary peritoneal cancer
- •2. Subject previously confirmed with endometriosis
- •3. Any women with any known active malignancy
- •4. Subjects with previous bilateral oophorectomy
- •5. Subjects known to be pregnant
- •6. Subjects with end-stage renal failure
- •7. Subjects who previously underwent an organ transplantation
研究者
相似试验
已完成
不适用
Evaluation of HE4 in ovarian cancerOvarian cancerJPRN-UMIN000037812ihon University Hospital59
已完成
不适用
Ovarian Cancer Risk Estimation in Patients With Pelvic MassAdnexal MassOvarian CancerNCT00987649Fujirebio Diagnostics, Inc.512
尚未招募
不适用
se of CA125,HE4 and Risk of ovarian malignancy(ROMA) index in ovarian cancerCTRI/2020/09/027922Maulana Azad Medical College
已完成
不适用
Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian CancerMetastatic Ovarian CancerNCT01768156Institut du Cancer de Montpellier - Val d'Aurelle101
已完成
不适用
HE4 as a Relapse Biomarker in Ovarian CancersOvarian CarcinomaNCT02595281Institut de Cancérologie de Lorraine90